Key result
Primary prophylactic CRT-D was not associated with better long-term survival compared to CRT-P after covariate adjustment, despite unadjusted annual mortality rates of.
Why the study?
Does primary prophylactic CRT-D improve long-term survival compared to CRT-P in patients with heart failure?
Cohort (n=705)
No
Does primary prophylactic CRT-D improve long-term survival compared to CRT-P in patients with heart failure?
Answers are grounded in this paper and cite their sources.
In a real-world retrospective cohort, primary prophylactic CRT-D was not associated with an independent long-term survival benefit over CRT-P after adjusting for baseline covariates.
BACKGROUND: Cardiac resynchronization therapy (CRT) with or without a defibrillator has a positive effect on mortality and morbidity for patients with heart failure. However, comparisons between CRT-defibrillators (CRT-D) and CRT-pacemakers (CRT-P) are relatively scarce outside the clinical trial setting. This study aimed to assess baseline characteristics in relation to long-term prognosis in patients treated with CRT, and to investigate the potential benefit of CRT-D versus CRT-P. METHODS: Data were retrospectively collected from the medical records of all consecutive patients treated with CRT-P or primary prophylactic CRT-D at a large tertiary care center between 1999 and 2012. Predictors of mortality were investigated, and time-dependent analysis was performed with all-cause mortality as the primary end point. RESULTS: A total of 705 patients were included (69.6 ± 10 years, 78% New York Heart Association classes III-IV, left ventricular ejection fraction median 25%, 16% female, 36% CRT-D). The patients were followed for a median of 59 months. Annual mortality differed between CRT-D primary prophylactic and CRT-P groups (5.3% and 11.8%, respectively), but when adjusted for covariates, CRT-D treatment (compared to CRT-P) was not associated with better long-term survival. Independent predictors of survival were: age, use of loop diuretics, hemoglobin levels, and use of renin angiotensin aldosterone system blockers. CONCLUSIONS: In CRT treatment outside of the clinical trial setting, CRT-D treatment was not an independent predictor of long-term survival. Future research should focus on correct selection of the patients who receive enough benefit of an added defibrillator to justify CRT-D implantation instead of CRT-P treatment only.
No takes yet. Share an insight, caveat, or question.
Reitan et al. (2015) conducted a cohort in Heart failure (n=705). Primary prophylactic CRT-defibrillators (CRT-D) vs. CRT-pacemakers (CRT-P) was evaluated on All-cause mortality. Primary prophylactic CRT-D was not associated with better long-term survival compared to CRT-P after covariate adjustment, despite unadjusted annual mortality rates of.
Synapse has enriched 10 related papers. Consider them for comparative context: